Hoth Therapeutics (HOTH) Projected to Post Earnings on Thursday

Hoth Therapeutics (NASDAQ:HOTH) is expected to be releasing its earnings data before the market opens on Thursday, March 27th. Analysts expect Hoth Therapeutics to post earnings of ($0.39) per share for the quarter.

Hoth Therapeutics Trading Down 1.9 %

Shares of NASDAQ HOTH opened at $1.04 on Thursday. Hoth Therapeutics has a 1-year low of $0.58 and a 1-year high of $3.80. The company has a market cap of $7.18 million, a PE ratio of -0.79 and a beta of 0.84. The company has a 50-day moving average of $1.22 and a two-hundred day moving average of $1.01.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on HOTH. D. Boral Capital reaffirmed a “buy” rating and issued a $5.00 target price on shares of Hoth Therapeutics in a research note on Monday, March 10th. HC Wainwright reaffirmed a “buy” rating and issued a $4.00 target price on shares of Hoth Therapeutics in a research note on Thursday, January 23rd.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.